A prospective and retrospectice, non-interventional observational study for efficacy and safety of Atazanavir/Ritonavir of HIV-infected woma
- Conditions
- B24Unspecified human immunodeficiency virus [HIV] disease
- Registration Number
- DRKS00000306
- Lead Sponsor
- Ruhr-Universität Bochum Klinik für Dermatologie und AllergologieKompetenznetz HIV/AIDS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 140
Inclusion Criteria
* Woman
* equal to or greater than 18 years
* HIV 1 positive
* Atazanavir/Ritonavir HAART at least 3 months
* Readiness to operate effective contraception during treatment
Exclusion Criteria
* Pregnant woman
* Known contraindication against Atazanavir and Ritonavir
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to virological failure and treatment discontinuation<br>Definied as:<br>- Loss to follow-up<br>- Drop-out<br>- Change of treatment due to intolerance ot toxicity<br>- Virological failure, defined as viral load > 400c/ml<br>- Clinical progression defined as apperance of a new AIDS event after the first month of treatment or death
- Secondary Outcome Measures
Name Time Method Detection of adverse drug reactions